JB-1
Based on 1 Customer Validation
JB-1, an IGF-I analog, is a selective IGF-I receptor inhibitor that does not interact with IGF-II. JB-1 competes with IGF-I for binding to IGF-1R and blocks receptor autophosphorylation. JB-1 increases the level of sVEGFR-1. JB-1 normalizes retinal abnormalities, including reducing retinal neovascularization. JB-1 is applicable to studies related to oxygen-induced retinopathy.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.63%
- CAS. Nr.: 147819-32-7
- Formel: C55H88N14O15S2
- Molecular Weight:1249.50
-
Speicherung:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Differentiation Inducing Compound Library
HY-L038
-
Macrocyclic Compound Library
HY-L041
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Peptide Library
HY-L105
-
Antidepressant Compound Library
HY-L108
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Antihypertensive Compound Library
HY-L145
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cytokine Inhibitors Library
HY-L161
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Peptide Compound Library
HY-L105S
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Anti-Aging Compound Library
HY-L034
Alle VEGFR Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
VEGFR-1 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley (newborn, pooled from timed-pregnant dams, assigned to expanded litters of 17 pups/litter, hyperoxia/hypoxia cycling exposed)[1]
-
Dosage:1 μg/day (JB1x3: P1, P2, P3); 1 μg/day (JB1x7: P1, P3, P5, P7, P9, P11, P13)
-
Administration:s.c.
-
Result:Increased body weight to 22.1 ± 0.51 g and linear growth to 6.0 ± 0.12 cm at P14 compared to saline-treated H/H littermates (JB1x3).
Increased serum sVEGFR-1 to 3562.5 ± 439.7 pg/mL at P14 compared to saline H/H (JB1x3).
Increased retinal VEGF and sVEGFR-1 levels at P14 compared to saline H/H (JB1x3).
Decreased retinal neovascularization area to 1.4 × 105 μm2 at P14 compared to saline H/H (2.0 × 105 μm2, p < 0.01) and JB1x7 H/H (1.7 × 105 μm2, p < 0.05) (JB1x3).
Resulted in all retinal flatmounts scoring <12 (no severe OIR) at P14 (JB1x3).
Sustained increased serum sVEGFR-1 to 6011.8 ± 800.2 pg/mL at P21 compared to saline H/H; downregulated VEGFA mRNA compared to saline H/H (JB1x3).
Decreased body weight to 17.5 ± 0.45 g and linear growth to 5.3 ± 0.10 cm at P14 compared to JB1x3 H/H (JB1x7).
Increased serum sVEGFR-1 to 5834.40 ± 903.5 pg/mL at P14 compared to saline H/H (JB1x7).
Decreased retinal sVEGFR-1 levels at P14 compared to saline H/H (JB1x7).
Decreased retinal neovascularization area to 1.7 × 105 μm2 at P14 compared to saline H/H (p < 0.05) (JB1x7).
Resulted in decreased body weight to 32.5 ± 1.00 g and linear growth to 6.4 ± 0.11 cm at P21 compared to saline H/H (JB1x7).
Suppressed serum sVEGFR-1 to 401.7 ± 31.7 pg/mL at P21 compared to saline H/H (JB1x7).
Resulted in extended retinal vascular overgrowth area to 2.6 × 105 μm2 (p < 0.01) similar to saline H/H, and 90% of retinal flatmounts scoring >12 (severe OIR) at P21 (JB1x7).
Upregulated VEGFA mRNA at P21 compared to JB1x3 H/H (JB1x7).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 147819-32-7
-
Appearance Solid
-
Molecular Weight 1249.50
-
Formel C55H88N14O15S2
-
Color White to off-white
-
Sequence
Cys-Tyr-Ala-Ala-Pro-Leu-Lys-Pro-Ala-Lys-Ser-Cys (Disulfide bridge: Cys1-Cys12)
-
Sequence Shortening
CYAAPLKPAKSC (Disulfide bridge: Cys1-Cys12)
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Lösungsmittel & Löslichkeit
H2O : ≥ 100 mg/mL (80.03 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (288 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.8003 mL | 4.0016 mL | 8.0032 mL | 20.0080 mL |
| 5 mM | 0.1601 mL | 0.8003 mL | 1.6006 mL | 4.0016 mL | |
| 10 mM | 0.0800 mL | 0.4002 mL | 0.8003 mL | 2.0008 mL | |
| 15 mM | 0.0534 mL | 0.2668 mL | 0.5335 mL | 1.3339 mL | |
| 20 mM | 0.0400 mL | 0.2001 mL | 0.4002 mL | 1.0004 mL | |
| 25 mM | 0.0320 mL | 0.1601 mL | 0.3201 mL | 0.8003 mL | |
| 30 mM | 0.0267 mL | 0.1334 mL | 0.2668 mL | 0.6669 mL | |
| 40 mM | 0.0200 mL | 0.1000 mL | 0.2001 mL | 0.5002 mL | |
| 50 mM | 0.0160 mL | 0.0800 mL | 0.1601 mL | 0.4002 mL | |
| 60 mM | 0.0133 mL | 0.0667 mL | 0.1334 mL | 0.3335 mL | |
| 80 mM | 0.0100 mL | 0.0500 mL | 0.1000 mL | 0.2501 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
JB-1 Related Classifications
HY-P3226 Related Classifications
Powered by Bioz